en
Scientific article
Open access
English

A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol

Published inBMC cancer, vol. 24, no. 1, 82
Publication date2024-01-15
First online date2024-01-15
Abstract

Background: Glioblastoma is the most common and most aggressive malignant primary brain tumor in adults. Glioblastoma cells synthesize and secrete large quantities of the excitatory neurotransmitter glutamate, driving epilepsy, neuronal death, tumor growth and invasion. Moreover, neuronal networks interconnect with glioblastoma cell networks through glutamatergic neuroglial synapses, activation of which induces oncogenic calcium oscillations that are propagated via gap junctions between tumor cells. The primary objective of this study is to explore the efficacy of brain-penetrating anti-glutamatergic drugs to standard chemoradiotherapy in patients with glioblastoma.

Methods/design: GLUGLIO is a 1:1 randomized phase Ib/II, parallel-group, open-label, multicenter trial of gabapentin, sulfasalazine, memantine and chemoradiotherapy (Arm A) versus chemoradiotherapy alone (Arm B) in patients with newly diagnosed glioblastoma. Planned accrual is 120 patients. The primary endpoint is progression-free survival at 6 months. Secondary endpoints include overall and seizure-free survival, quality of life of patients and caregivers, symptom burden and cognitive functioning. Glutamate levels will be assessed longitudinally by magnetic resonance spectroscopy. Other outcomes of interest include imaging response rate, neuronal hyperexcitability determined by longitudinal electroencephalography, Karnofsky performance status as a global measure of overall performance, anticonvulsant drug use and steroid use. Tumor tissue and blood will be collected for translational research. Subgroup survival analyses by baseline parameters include segregation by age, extent of resection, Karnofsky performance status, O6-methylguanine DNA methyltransferase (MGMT) promotor methylation status, steroid intake, presence or absence of seizures, tumor volume and glutamate levels determined by MR spectroscopy. The trial is currently recruiting in seven centers in Switzerland.

Trial registration: NCT05664464. Registered 23 December 2022.

eng
Keywords
  • Cancer neuroscience
  • Epilepsy
  • Gabapentin
  • Memantine
  • Sulfasalazine
  • Adult
  • Humans
  • Glioblastoma / drug therapy
  • Glioblastoma / genetics
  • Temozolomide / therapeutic use
  • Quality of Life
  • Drug Repositioning
  • Chemoradiotherapy
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / genetics
  • Steroids / therapeutic use
  • Glutamates
  • Randomized Controlled Trials as Topic
  • Multicenter Studies as Topic
  • Clinical Trials, Phase I as Topic
Citation (ISO format)
MASTALL, Maximilian et al. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. In: BMC cancer, 2024, vol. 24, n° 1, p. 82. doi: 10.1186/s12885-023-11797-z
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal1471-2407
18views
2downloads

Technical informations

Creation01/20/2024 7:49:56 AM
First validation01/30/2024 4:25:38 PM
Update time01/30/2024 4:25:38 PM
Status update01/30/2024 4:25:38 PM
Last indexation01/30/2024 4:25:38 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack